So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes ...

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary review to be potentially included in China's basic medical insurance drug ...

Pfizer (NYSE:PFE) has announced a new CFO transition as Dave Denton prepares to step down in August, adding another management change at a time when the drugmaker is still working to rebuild growth ...

BEIJING, June 29 (Reuters) - Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a ...

Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very ...

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts ...

McDonald's and Pfizer are blue-chip laggards trading at a discount, and both promise retirees a place to park serious money.

It could prove to be a case of better later than never for the healthcare giant.

Drug pricing matters, but pipelines matter even more.